More on the Survival and Ventricular Enlargement Trial

C. J. Ganley, H. M J Hung, R. Temple, M. A. Pfeffer, L. A. Moye, J. Rutherford, E. Braunwald

Research output: Contribution to journalLetter

12 Scopus citations

Abstract

To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue)1 reported that significantly fewer patients given captopril had at least one recurrent infarction (170 patients in the placebo group and 133 in the captopril group). This result is not as clear-cut as the report suggests. The favorable finding arose from a post hoc reanalysis of the data. The protocol of the Survival and Ventricular Enlargement (SAVE) trial precisely defined the criteria for recurrent myocardial infarction: 1) new Q or QS waves…

Original languageEnglish (US)
Pages (from-to)1204-1206
Number of pages3
JournalNew England Journal of Medicine
Volume329
Issue number16
DOIs
StatePublished - Oct 14 1993

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'More on the Survival and Ventricular Enlargement Trial'. Together they form a unique fingerprint.

Cite this